Skip to main content
. 2012 Jun 6;92(1):96–102. doi: 10.1038/clpt.2012.20

Figure 1.

Figure 1

Plasma concentration–time profiles of MK-7246 after administration of a single 40-mg dose of MK-7246 in the fasted state in individuals in panels (a) A and (b) B of the first-in-human study. Eight subjects, including two who received the placebo, participated in each panel. Each symbol and line represents a separate individual who received MK-7246 within each panel.